Autolus appoints Elisabeth Leiderman to board; Kapil Dhingra resigns

Autolus Therapeutics plc

Kapil Dhingra resigned from Board effective Dec 31, 2023; not due to any disagreement with company.
Elisabeth Leiderman appointed as Class II director effective Dec 20, 2023; will serve on Audit Committee.
Leiderman receives £52,500 annual retainer, £6,500 audit committee retainer, and option to purchase 80,000 ADSs at $5.50.
Leiderman most recently CFO/CBO of Atsena Therapeutics; also serves on bluebird bio board.
Press release also notes BLA submission for obe-cel in r/r adult B-ALL to FDA.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kapil Dhingra

Director

AUTL · Autolus Therapeutics plc

Effective: 2023-12-31
Filed: December 22, 2023, 6:59 PM ET

On December 19, 2023, Kapil Dhingra, M.D. notified Autolus Therapeutics plc (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company and its committees, effective December 31, 2023.

Appointed

Elisabeth Leiderman

Director

AUTL · Autolus Therapeutics plc

Effective: 2023-12-20
Filed: December 22, 2023, 6:59 PM ET

On December 22, 2023, the Company announced that the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Elisabeth (“Lis”) Leiderman, M.D. to serve as a Class II director of the Company, effective December 20, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kapil Dhingra resigned as Director at Autolus Therapeutics plc.

Action: resigned
Role: Director

Exact text from the filing

On December 19, 2023, Kapil Dhingra, M.D. notified Autolus Therapeutics plc (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company and its committees, effective December 31, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Elisabeth Leiderman was appointed as Director at Autolus Therapeutics plc.

Action: appointed
Role: Director

Exact text from the filing

On December 22, 2023, the Company announced that the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Elisabeth (“Lis”) Leiderman, M.D. to serve as a Class II director of the Company, effective December 20, 2023.

View on SEC.gov

Autolus Therapeutics plc filing history →

Source: SEC EDGAR

accession 0001730463-23-000125

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.